Table 3

Endpoint analysis of global and segmental circumferential strain between baseline and 6 months in whole cohort



Mean (SD)Coefficient (between-group p value)
PlaceboCAP-1002 groupUnadjustedAdjusted for LV scar per centAdjusted for LVEDViAdjusted for LVEDVi and scar per cent
All segments
 Segmental Ecc at baseline, %−9.7 (5.1)−9.9 (5.2)−0.58 (0.05)−0.62 (0.02)−0.49 (0.11)−0.51 (0.06)
 Segmental Ecc at 6 months, %−9.5 (5.0)−10.4 (5.3)
 Within-group p value0.25<0.001
 Change in segmental Ecc, %0.2 (3.7)−0.5 (4.0)
Remote segments
 Segmental Ecc at baseline, %−12.2 (5.1)12.5 (5.0)−0.56 (0.22)−0.52 (0.27)
 Segmental Ecc at 6 months, %−11.8 (5.2)−12.7 (5.5)
 Within-group p value0.110.22
 Change in segmental Ecc, %0.4 (3.8)−0.2 (4.5)
Infarcted segments
 Segmental Ecc at baseline, %−8.3 (4.5)−8.1 (4.6)−0.63 (0.04)−0.53 (0.09)
 Segmental Ecc at 6 months, %−8.2 (4.4)−8.8 (4.5)
 Within-group p value0.82<0.001
 Change in segmental Ecc, %0.04 (3.7)−0.7 (3.5)
Global Ecc at baseline, %−8.4 (2.3)−8.3 (2.9)−0.63 (0.15)−0.65 (0.14)−0.53 (0.25)−0.57 (0.20)
Global Ecc at 6 months, %−8.3 (2.5)−8.9 (3.0)
Within-group p value0.650.03
Change in global Ecc, %0.1 (1.9)−0.6 (2.6)
  • The regression coefficients represent the relative difference in the slope of change from baseline to 6 months between CAP-1002 and placebo groups.

  • Bold font indicates statistical significance.

  • Ecc, circumferential strain; LVEDVi, left ventricular end-diastolic volume index.